Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
ESKD, end-stage kidney disease
These typically include: Nausea, especially after eating large meals Reduced appetite, which is partly how the medication works Occasional digestive discomfort during the adjustment period Changes in bowel habits Most of these symptoms improve as your body adjusts to the medication
Laboratory research record on IGF-1 LR3 [PMID: 24882635] PubMed laboratory record discussing IGF-1 LR3 in a research context
S14, 13641374 (2005)
US$ 26.27
US$ 27.62
US$ 21.58
US$ 22.42
US$ 27.03
US$ 26.14
US$ 24.87
